Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander report beneficial ownership of 906,762 shares of Avalo Therapeutics, Inc. common stock, representing 4.9% of the class. They hold shared voting and dispositive power over these shares and no sole power.
The filing notes they briefly owned more than 5% of Avalo’s outstanding common stock on February 3, 2026, but were below the 5% threshold by the date of this statement. The reporting persons state the shares were not acquired to change or influence control of Avalo.
SilverArc Capital Management, LLC and Devesh Gandhi have filed a Schedule 13G reporting a passive ownership stake in Avalo Therapeutics, Inc. Class A common stock. As of the event date, they beneficially own 524,436 shares, representing 2.83% of the outstanding Class A common stock.
All 524,436 shares are reported with shared voting and shared dispositive power, and neither SilverArc nor Gandhi has sole voting or dispositive power over any shares. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics.
Avalo Therapeutics, Inc. received a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 905,798 shares of Avalo common stock, representing 4.9% of the class.
The filing notes that the reporting persons exceeded 5% beneficial ownership of Avalo’s common stock on January 28, 2026, but had reduced their holdings to 4.9% by the date of the statement. Voting and investment power over these shares is reported as shared, with no sole voting or dispositive power.
The Vanguard Group filed an amended Schedule 13G reporting passive ownership in Avalo Therapeutics Inc common stock.
Vanguard reports beneficial ownership of 804,084 shares, representing 4.43% of Avalo’s common stock as of the event date. It has no sole voting or dispositive power, with shared voting power over 92,039 shares and shared dispositive power over 804,084 shares.
The filing states the holdings are in the ordinary course of business and not for changing or influencing control. Vanguard notes a January 12, 2026 internal realignment, after which certain subsidiaries are expected to report ownership separately while continuing the same investment strategies.
Affinity Asset Advisors, LLC and Michael Cho reported beneficial ownership in Avalo Therapeutics, Inc. common stock totaling 1,051,054 shares, or about 5.7% of the company. The shares are held through Affinity Healthcare Fund, LP, with Affinity acting as investment manager and exercising voting and investment power.
The ownership percentage is based on 18,512,757 Avalo shares outstanding as of December 31, 2025, as disclosed in Avalo’s Form S-3 filed on January 8, 2026. The reporting persons state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo.
Avalo Therapeutics, Inc. reported that it estimates having approximately $98 million in cash, cash equivalents and short-term investments as of December 31, 2025, based on figures shared in an updated investor presentation.
The company emphasized that this cash estimate is unaudited, preliminary and does not include full details of its financial condition or results for the year, which will be provided in its future annual report. Avalo also made the updated investor presentation available on its website and attached it as an exhibit to this report for use in meetings with investors.
Avalo Therapeutics, Inc. has filed a shelf registration statement that allows it to offer up to $750,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The filing also carries forward $326,585,963 of previously registered but unsold securities from an expiring shelf under SEC Rule 415(a)(6), so those amounts remain available without interruption. Proceeds from future offerings may be used for general corporate purposes, including clinical trials, research and development, and general and administrative expenses. Avalo is a clinical-stage biotechnology company focused on IL‑1β-based therapies, led by AVTX‑009 in a Phase 2 trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.
Avalo Therapeutics, Inc. reported an insider Form 4 transaction by its Chief Medical Officer. On December 10, 2025, the officer disposed of 1,013 shares of Avalo Therapeutics common stock at $4.1 per share. After this transaction, the officer beneficially owns 3,622 shares, which include shares acquired pursuant to Avalo Therapeutics' Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics’ chief strategy officer reported a small change in personal share holdings. On 12/10/2025, the officer disposed of 637 shares of Avalo Therapeutics common stock at a price of $4.1 per share, according to an SEC insider ownership report.
After this transaction, the officer directly beneficially owns 2,655 shares of Avalo Therapeutics. These 2,655 shares are described as having been acquired under the company’s Employee Stock Purchase Plan as part of the reported activity, indicating ongoing participation in the company’s equity programs.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
